| Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma (NCT04386772) | Eastern Hepatobiliary Surgery Hospital | 2020-05-27 |
| COVID-19 Infection in Patients With Hepatocellular Carcinoma (NCT04367805) | Centre Hospitalier Universitaire, Amiens | 2020-05-22 |
| Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus (NCT04319484) | RenJi Hospital | 2020-05-02 |
| Primary Hepatobiliary Cancer Cohort of Central China (NCT05520801) | Tongji Hospital | 2020-05-01 |
| Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing (NCT05520788) | Tongji Hospital | 2020-05-01 |
| Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation (NCT04237740) | RenJi Hospital | 2020-05-01 |
| TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma (NCT04297280) | Fudan University | 2020-04-29 |
| Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC (NCT05729867) | Seoul National University Hospital | 2020-04-27 |
| Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence (NCT04213118) | First Affiliated Hospital Xi'an Jiaotong University | 2020-04-23 |
| Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors (NCT04374877) | Coherus Oncology, Inc. | 2020-04-22 |
| AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma (NCT04368182) | Zhejiang University | 2020-04-13 |
| "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma (NCT04317248) | Yuehua Huang | 2020-04-01 |
| Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria; (NCT04738188) | Beijing Tsinghua Chang Gung Hospital | 2020-03-18 |
| NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors (NCT04270461) | Jiujiang University Affiliated Hospital | 2020-03-17 |
| Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) (NCT04170556) | Fundacion Clinic per a la Recerca Biomédica | 2020-03-16 |
| Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) (NCT04123379) | Icahn School of Medicine at Mount Sinai | 2020-03-05 |
| Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients (NCT04601961) | The University of Hong Kong | 2020-03-04 |
| TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (NCT04490694) | Shanghai Zhongshan Hospital | 2020-03-01 |
| Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant (NCT03960008) | Lahey Clinic | 2020-03-01 |
| Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C (NCT04220151) | Assiut University | 2020-03-01 |
| Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE (NCT04150874) | H. Lee Moffitt Cancer Center and Research Institute | 2020-02-19 |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (NCT04244552) | Atreca, Inc. | 2020-02-11 |
| A Multicenter Cancer Biospecimen Collection Study (NCT04510129) | Cofactor Genomics, Inc. | 2020-02-05 |
| Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma With Twin Cooled-wet Electrodes (NCT05449860) | Seoul National University Hospital | 2020-01-28 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis (NCT04187872) | University of Florida | 2020-01-10 |
| Radiofrequency Ablation With Gradual Radiofrequency Energy Increment for Hepatocellular Carcinoma Treatment (NCT05397860) | Seoul National University Hospital | 2020-01-06 |
| T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) (NCT04093648) | Baylor College of Medicine | 2020-01-01 |
| Role of LncRNA H19 in The Regulation of IGF-1R Expression (NCT04767750) | Mansoura University | 2020-01-01 |
| A Survey for Factors That Influence Postoperative Treatment Decision-making for Hepatocellular Carcinoma (NCT04239781) | Shanghai Zhongshan Hospital | 2020-01-01 |
| Liver Disease and Other Systemic Diseases (NCT04525833) | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 2020-01-01 |
| A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients (NCT02289300) | A2 Healthcare Taiwan Corporation | 2020-01-01 |
| To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma (NCT04365751) | Chinese PLA General Hospital | 2019-12-26 |
| A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic Hemihepatectomy (NCT04422249) | Southwest Hospital, China | 2019-12-23 |
| Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence (NCT05823584) | TCM Biotech International Corp. | 2019-12-22 |
| Neo-TACE-HAIC for PVTT-HCC (NCT04181931) | Sun Yat-sen University | 2019-12-16 |
| A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma (NCT04194801) | CStone Pharmaceuticals | 2019-12-16 |
| A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma (NCT04194775) | CStone Pharmaceuticals | 2019-12-13 |
| Longitudinal Immune-phenotyping of HCC Following MK-3475 (NCT04224480) | National Cancer Centre, Singapore | 2019-12-10 |
| An Intraoperative Guidance Platform for Radio Frequency Ablation (NCT04152343) | Dartmouth-Hitchcock Medical Center | 2019-12-07 |
| Blood Sample Collection for Experimental Blood Test to Track Liver Cancer (NCT04720430) | Thomas Jefferson University | 2019-12-03 |
| Combined Radiotherapy and Radiofrequency Ablation for Hepatocellular Carcinoma (NCT04202523) | Guangxi Medical University | 2019-12-01 |
| Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma (NCT03908840) | Evolve Biologics | 2019-12-01 |
| SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma (NCT04297202) | The First Affiliated Hospital with Nanjing Medical University | 2019-12-01 |
| Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy. (NCT06248528) | Chen Xiaoping | 2019-12-01 |
| Changing Trends in HCC Procedures (NCT04163627) | University Hospital, Montpellier | 2019-11-30 |
| Discrepancies in Management of Hepatocellualr Carcinoma Between Practice and Recommendations (NCT04189809) | University Hospital, Montpellier | 2019-11-30 |
| Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC (NCT04157140) | Jinglong Chen | 2019-11-28 |
| Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis (NCT04104074) | Beijing Tsinghua Chang Gung Hospital | 2019-11-25 |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320) | Craig L Slingluff, Jr | 2019-11-21 |
| Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC (NCT04174781) | Zhejiang University | 2019-11-20 |
| Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis (NCT04170179) | Sun Yat-sen University | 2019-11-19 |
| Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT (NCT04169399) | Sun Yat-sen University | 2019-11-17 |
| Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) (NCT04167293) | Mian XI | 2019-11-16 |
| Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors (NCT04157985) | Dan Zandberg | 2019-11-15 |
| Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma (NCT04168944) | RenJi Hospital | 2019-11-01 |
| Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection (NCT04044651) | Shi Ming | 2019-10-30 |
| A Study of LY3435151 in Participants With Solid Tumors (NCT04099277) | Eli Lilly and Company | 2019-10-28 |
| Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis (NCT04160897) | Qing XIe | 2019-10-22 |
| HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial (NCT04135690) | Sun Yat-sen University | 2019-10-20 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC (NCT04121273) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2019-10-05 |
| TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma (NCT04103398) | Sun Yat-sen University | 2019-10-02 |
| CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab (NCT03638141) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-10-02 |
| A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma (NCT03970616) | AVEO Pharmaceuticals, Inc. | 2019-09-30 |
| A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (NCT04039607) | Bristol-Myers Squibb | 2019-09-30 |
| Prospective Cohort of Patients With Hepatocellular Carcinoma in France (NCT04348838) | Centre Hospitalier Universitaire, Amiens | 2019-09-26 |
| A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients (NCT03973112) | Shanghai Henlius Biotech | 2019-09-24 |
| Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma (NCT04080154) | Shanghai Zhongshan Hospital | 2019-09-24 |
| Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers (NCT04077372) | Stanford University | 2019-09-16 |
| Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC (NCT04143191) | Sun Yat-sen University | 2019-09-15 |
| Nivolumab Combined With BMS-986253 in HCC Patients (NCT04050462) | NYU Langone Health | 2019-09-12 |
| Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway (NCT04209491) | Assistance Publique - Hôpitaux de Paris | 2019-09-09 |
| Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) (NCT03963206) | Hospices Civils de Lyon | 2019-09-09 |
| A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors (NCT06239155) | Ascentawits Pharmaceuticals, Ltd | 2019-09-03 |
| Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE (NCT03642561) | Fudan University | 2019-09-03 |
| Predictive Model for Pain After TACE (NCT05545046) | Yantai Yuhuangding Hospital | 2019-09-01 |
| HepATocellular Cancer Hcv Therapy Study (NCT04546802) | Bayside Health | 2019-09-01 |
| Chimeric Antigen Receptor T Cells Targeting Glypican-3 (NCT03884751) | CARsgen Therapeutics Co., Ltd. | 2019-08-15 |
| RFA Versus SBRT for Recurrent Small HCC (NCT04047173) | Sun Yat-sen University | 2019-08-12 |
| AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma (NCT03971747) | Shanghai AbelZeta Ltd. | 2019-08-06 |
| HAIC Plus Lenvatinib and Toripalimab for Advanced HCC (NCT04044313) | Shi Ming | 2019-08-01 |
| Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma (NCT04076631) | Chen Xiaoping | 2019-08-01 |
| Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma (NCT04042805) | Baocai Xing | 2019-08-01 |
| Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma (NCT04926532) | Shanghai Zhongshan Hospital | 2019-08-01 |
| Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma (NCT03781960) | Abramson Cancer Center at Penn Medicine | 2019-07-31 |
| Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carinoma (NCT03079778) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2019-07-31 |
| Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells (NCT04032392) | Beijing 302 Hospital | 2019-07-23 |
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients (NCT03916627) | Regeneron Pharmaceuticals | 2019-07-23 |
| TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma (NCT03996681) | Suzhou Municipal Hospital | 2019-07-20 |
| Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant (NCT04035876) | Zhejiang University | 2019-07-16 |
| Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial (NCT06193733) | Chang Gung Memorial Hospital | 2019-07-01 |
| 68 Ga PSMA PET/MRI for Hepatocellular Carcinoma (NCT03982407) | Ajit H. Goenka, MD | 2019-06-27 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy (NCT04106167) | Fate Therapeutics | 2019-06-11 |
| Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers (NCT03785210) | National Cancer Institute (NCI) | 2019-06-05 |
| SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma (NCT04014101) | Shanghai Zhongshan Hospital | 2019-06-01 |
| Personalized DC Vaccine for Postoperative Cancer (NCT04147078) | Sichuan University | 2019-06-01 |
| Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma (NCT03998033) | Eureka Therapeutics Inc. | 2019-05-30 |
| ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer (NCT03965546) | First Affiliated Hospital Xi'an Jiaotong University | 2019-05-30 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469) | Xencor, Inc. | 2019-05-29 |